Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job
Symposium

[Free Online] The Science and Stories of Promising Biotech Startups


Speakers: Ritu Lal, Gen1E Lifesciences; Shilpa Sambashivan, Nura; Stefan Ryser, Trellis Bio; Keting Chu, Bluejay; Annahita Keravala, Genascence; Shelley Force Aldred, Rondo Therapeutics; Donald McCarthy, Samsara BioCapital
Organizers: Toby Freedman (Synapsis Search); Sarah Bodary (AbCellera); Donald McCarthy (Samsara BioCapital); Shichang Miao (PBSS)
Date: 2023-08-17
Time: 8:30-13:30 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2023-08-16  (it will close sooner if the seating cap is reached)

About the Topic

This symposium series aims to provide a platform for promising biotech startup companies to highlight their science and share their stories in building a fledgling business.

Pacific Time

Eastern Time

Topic

Presenter

8:30 - 8:40 am

11:30 -11:40 am

Welcome Remarks

Shichang Miao, PBSS

8:40 - 9:15 am

11:40 am -12:15 pm

Clinical-Stage Company in Phase 2 with a Multi-Target AI Platform Accelerating Therapies for Inflammatory and Rare Diseases

Ritu Lal, M.S, PhD, CEO, Gen1e Lifesciences Inc. 

9:15 -9:50 am

12:15 - 12:50 pm

Discovery and Development of Neuroprotective Therapies for the Treatment of Neurological Diseases

Shilpa Sambashivan, PhD, CSO, Nura Bio Inc.

9:50 -10:25 am

12:50 - 1:25 pm

Clinical Proof-of-Concept in a Difficult-to-Treat Infection, human mAb TRL1068 Overcomes Antibiotic Resistance Due to Bacterial Biofilm

Stefan Ryser, PhD, President & CEO, Trellis Bioscience, Inc.

10:25 -11:00 am

1:25 - 2:00 pm

Development of Functional Cure for Chronic HBV Infection

Keting Chu, MD, PHD, CEO & Founder, Bluejay Therapeutics, Inc.

11:00 -11:10 am

2:00 - 2:10 pm

Break Time

  

11:10 - 11:45 pm

2: 10 – 2:45 pm

AAV-Mediated Gene Therapy for Osteoarthritis

Annahita Kervala, PhD, CSO, Genascence

11:45 am- 12:20 pm

2:45 – 3:20 pm

Tackling Solid Tumors with Next-Generation Bispecific Antibodies

Shelley Force Aldred, PhD, CEO & Co-founder, Rondo Therapeutics

12: 20 – 12:55 pm

3:20 – 3:55 pm

Raising capital in today's environment

Donald McCarthy, PhD, VP, Samsara BioCapital

12:55 – 1:30 pm

3:55 – 4:30 pm

Panel Discussion

All Speakers

The Zoom link will be sent one day before the symposium.

Other Events of PBSS-San Francisco Bay:

2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
©Pharmaceutical & BioScience Society, International; Last Modified: 4/19/2024; Admin Logon
 Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad